Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 19/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.40 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.40 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48534 | 0.90 | PIK3CG (0.64) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| Sulfuric Acid SCHEMBL17203250 | 0.88 | PIK3CG (0.62) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| Sulfuric Acid SCHEMBL17202951 | 0.87 | PIK3CG (0.61) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| Sulfuric Acid SCHEMBL17203127 | 0.87 | PIK3CG (0.61) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| Sulfuric Acid SCHEMBL17202949 | 0.87 | PIK3CG (0.61) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL48826 | 0.87 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| Sulfuric Acid SCHEMBL17203266 | 0.87 | PIK3CG (0.61) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL1787009 | 0.87 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL1784761 | 0.87 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL49251 | 0.86 | PIK3CD (0.52) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129541-B2 | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-1480962-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| EP-2311818-A1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | Novartis AG (CH) | 2011-04-20 | — | — | EP | disclosed |
| US-7902375-B2 | Antiallergens; antiarthritic agents; psoriasis; inflammatory bowel disorders; Crohn's disease; sepsis ; antiproliferative agents; anticancer agents; transplant rejection; stroke; antidiabetic agents; restenosis | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK1 | PIK3CD 12/4885PIK3CG 6/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.